LifeTech Scientific Corporation
LifeTech Scientific Corporation 1302.HK Peers
See (1302.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 1302.HK | $1.55 | -0.65% | 6.82B | 31.00 | $0.05 | N/A |
| 2252.HK | $16.52 | -8.12% | 16.51B | -23.60 | -$0.70 | N/A |
| 0853.HK | $6.81 | -1.16% | 12.60B | -7.24 | -$0.94 | N/A |
| 1789.HK | $5.69 | -1.56% | 6.35B | 21.88 | $0.26 | +0.79% |
| 6606.HK | $14.14 | N/A | 6.32B | 61.48 | $0.23 | N/A |
| 2172.HK | $10.76 | -0.37% | 6.21B | 22.89 | $0.47 | +1.77% |
| 2190.HK | $19.48 | +0.93% | 6.08B | 59.03 | $0.33 | N/A |
| 1858.HK | $9.55 | -1.55% | 5.64B | 28.09 | $0.34 | +5.11% |
| 1763.HK | $11.68 | +0.52% | 3.75B | 8.59 | $1.36 | +6.31% |
| 9996.HK | $5.44 | -4.56% | 3.62B | -15.11 | -$0.36 | N/A |
Stock Comparison
1302.HK vs 2252.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2252.HK has a market cap of 16.51B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2252.HK trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2252.HK's P/E ratio is -23.60. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2252.HK's ROE of -2.32%. Regarding short-term risk, 1302.HK is less volatile compared to 2252.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 0853.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 0853.HK has a market cap of 12.60B. Regarding current trading prices, 1302.HK is priced at $1.55, while 0853.HK trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 0853.HK's P/E ratio is -7.24. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 0853.HK's ROE of -0.33%. Regarding short-term risk, 1302.HK is less volatile compared to 0853.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 1789.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 1789.HK has a market cap of 6.35B. Regarding current trading prices, 1302.HK is priced at $1.55, while 1789.HK trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 1789.HK's P/E ratio is 21.88. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 1789.HK's ROE of +0.11%. Regarding short-term risk, 1302.HK is less volatile compared to 1789.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 6606.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 6606.HK has a market cap of 6.32B. Regarding current trading prices, 1302.HK is priced at $1.55, while 6606.HK trades at $14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 6606.HK's P/E ratio is 61.48. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 6606.HK's ROE of -0.04%. Regarding short-term risk, 1302.HK is less volatile compared to 6606.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2172.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2172.HK has a market cap of 6.21B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2172.HK trades at $10.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2172.HK's P/E ratio is 22.89. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2172.HK's ROE of +0.15%. Regarding short-term risk, 1302.HK is less volatile compared to 2172.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2190.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2190.HK has a market cap of 6.08B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2190.HK trades at $19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2190.HK's P/E ratio is 59.03. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2190.HK's ROE of +0.03%. Regarding short-term risk, 1302.HK is more volatile compared to 2190.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 1858.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 1858.HK has a market cap of 5.64B. Regarding current trading prices, 1302.HK is priced at $1.55, while 1858.HK trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 1858.HK's P/E ratio is 28.09. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 1858.HK's ROE of +0.04%. Regarding short-term risk, 1302.HK is less volatile compared to 1858.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 1763.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 1763.HK has a market cap of 3.75B. Regarding current trading prices, 1302.HK is priced at $1.55, while 1763.HK trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 1763.HK's P/E ratio is 8.59. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 1763.HK's ROE of +0.08%. Regarding short-term risk, 1302.HK is more volatile compared to 1763.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 9996.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 9996.HK has a market cap of 3.62B. Regarding current trading prices, 1302.HK is priced at $1.55, while 9996.HK trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 9996.HK's P/E ratio is -15.11. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 9996.HK's ROE of -0.11%. Regarding short-term risk, 1302.HK is less volatile compared to 9996.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2235.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2235.HK has a market cap of 2.61B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2235.HK trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2235.HK's P/E ratio is -39.50. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2235.HK's ROE of -0.03%. Regarding short-term risk, 1302.HK is more volatile compared to 2235.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2500.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2500.HK has a market cap of 2.46B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2500.HK trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2500.HK's P/E ratio is -3.23. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2500.HK's ROE of -0.23%. Regarding short-term risk, 1302.HK is less volatile compared to 2500.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 6669.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 6669.HK has a market cap of 2.37B. Regarding current trading prices, 1302.HK is priced at $1.55, while 6669.HK trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 6669.HK's P/E ratio is 44.00. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 6669.HK's ROE of +0.04%. Regarding short-term risk, 1302.HK is less volatile compared to 6669.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2160.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2160.HK has a market cap of 2.00B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2160.HK trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2160.HK's P/E ratio is -41.50. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2160.HK's ROE of -0.02%. Regarding short-term risk, 1302.HK is more volatile compared to 2160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 1696.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 1696.HK has a market cap of 1.91B. Regarding current trading prices, 1302.HK is priced at $1.55, while 1696.HK trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 1696.HK's P/E ratio is 9.69. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 1696.HK's ROE of +0.05%. Regarding short-term risk, 1302.HK is more volatile compared to 1696.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2216.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2216.HK has a market cap of 1.21B. Regarding current trading prices, 1302.HK is priced at $1.55, while 2216.HK trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2216.HK's P/E ratio is -10.00. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2216.HK's ROE of -0.09%. Regarding short-term risk, 1302.HK is less volatile compared to 2216.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 6609.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 6609.HK has a market cap of 1.09B. Regarding current trading prices, 1302.HK is priced at $1.55, while 6609.HK trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 6609.HK's P/E ratio is -71.79. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 6609.HK's ROE of -0.01%. Regarding short-term risk, 1302.HK is less volatile compared to 6609.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2170.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2170.HK has a market cap of 803.94M. Regarding current trading prices, 1302.HK is priced at $1.55, while 2170.HK trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2170.HK's P/E ratio is -2.99. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2170.HK's ROE of -0.20%. Regarding short-term risk, 1302.HK is less volatile compared to 2170.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 6118.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 6118.HK has a market cap of 399.81M. Regarding current trading prices, 1302.HK is priced at $1.55, while 6118.HK trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 6118.HK's P/E ratio is 26.00. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 6118.HK's ROE of +0.02%. Regarding short-term risk, 1302.HK is less volatile compared to 6118.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 1612.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 1612.HK has a market cap of 260.55M. Regarding current trading prices, 1302.HK is priced at $1.55, while 1612.HK trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 1612.HK's P/E ratio is 3.68. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 1612.HK's ROE of +0.12%. Regarding short-term risk, 1302.HK is more volatile compared to 1612.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2297.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2297.HK has a market cap of 209.04M. Regarding current trading prices, 1302.HK is priced at $1.55, while 2297.HK trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2297.HK's P/E ratio is -1.63. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2297.HK's ROE of -0.26%. Regarding short-term risk, 1302.HK is more volatile compared to 2297.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1302.HK.
1302.HK vs 2393.HK Comparison
1302.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1302.HK stands at 6.82B. In comparison, 2393.HK has a market cap of 172.54M. Regarding current trading prices, 1302.HK is priced at $1.55, while 2393.HK trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1302.HK currently has a P/E ratio of 31.00, whereas 2393.HK's P/E ratio is 0.18. In terms of profitability, 1302.HK's ROE is +0.06%, compared to 2393.HK's ROE of +1.71%. Regarding short-term risk, 1302.HK is less volatile compared to 2393.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1302.HK.